AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Rosuvastatin ORBITAL Germany

Phase 3

Completed

Conditions: Hypercholesterolemia

First Posted Date: 2006-09-21

Last Posted Date: 2009-03-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 8000

Registration Number: NCT00379249

Airway Clearance Study

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

First Posted Date: 2006-09-21

Last Posted Date: 2011-01-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 54

Registration Number: NCT00379028

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Phase 2

Completed

Conditions: Renal Cell Carcinoma
Patients Who Have/Have Had Melanoma and Other Tumors
Colorectal Neoplasms
Prostatic Neoplasms
Neoplasms
Melanoma

Interventions: Drug: CP-675,206 (Tremelimumab)

First Posted Date: 2006-09-20

Last Posted Date: 2024-08-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 37

Registration Number: NCT00378482

Locations: 🇬🇧
Research Site, Newecastle Upon Tyne, United Kingdom

Effect on Weight Loss of Exenatide Versus Placebo

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: exenatide
Drug: placebo

First Posted Date: 2006-09-13

Last Posted Date: 2015-04-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 196

Registration Number: NCT00375492

Locations: 🇺🇸
Research Site, Renton, Washington, United States

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: Saxagliptin
Drug: Metformin (blinded)
Drug: Metformin (open-label)

First Posted Date: 2006-09-12

Last Posted Date: 2015-05-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 156

Registration Number: NCT00374907

Locations: 🇺🇸
Diabetes & Glandular Disease Research Assoc,, Inc., San Antonio, Texas, United States
🇺🇸
Va San Diego Healthcare System, San Diego, California, United States
🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

Phase 1

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: CP-675,206
Drug: SU011248

First Posted Date: 2006-09-07

Last Posted Date: 2012-06-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 28

Registration Number: NCT00372853

Locations: 🇺🇸
Research Site, Memphis, Tennessee, United States

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: capecitabine
Drug: AZD6244

First Posted Date: 2006-09-07

Last Posted Date: 2014-08-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 70

Registration Number: NCT00372944

Locations: 🇷🇴
Research Site, Cluj-Napoca, Romania

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: AZD6244

First Posted Date: 2006-09-07

Last Posted Date: 2014-08-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 88

Registration Number: NCT00372788

Locations: 🇷🇴
Research Site, Cluj-Napoca, Romania

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Aclidinium bromide
Drug: Placebo

First Posted Date: 2006-08-15

Last Posted Date: 2017-01-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 843

Registration Number: NCT00363896

Locations: 🇫🇷
Almirall Investigational Sites#669, Montpellier,cedex 5, France
🇩🇰
Almirall Investigational Sites#397, Odense C., Denmark
🇩🇪
Almirall Investigational Sites#757, Jena, Germany

and more 128 locations

A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: exenatide
Drug: insulin glargine

First Posted Date: 2006-08-04

Last Posted Date: 2015-04-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 235

Registration Number: NCT00360334

Locations: 🇬🇧
Research Site, Wirral, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy